Gout, a painful form of inflammatory arthritis, is set to become far more common in the coming decades. According to projections, the global prevalence of gout is expected to rise significantly over the next twenty-five years, driven by aging populations, rising obesity rates, and lifestyle factors. In the United States alone, over 9 million people have already been diagnosed with the disease, while 44 million people have uric acid levels above the normal range, placing them at risk of developing gout. This looming public health challenge underscores the urgent need for better treatment options, as current therapies often come with intolerable side effects that lead to poor patient adherence.
Existing gout treatments, particularly oral xanthine oxidase inhibitors, are effective for many but not all. Approximately 3% to 5% of patients cannot tolerate these drugs, and they carry boxed warnings for cardiovascular risk. Some medications can cause severe gastrointestinal issues, kidney toxicity, and even trigger more gout flare-ups initially, discouraging patients from continuing treatment. These limitations create a significant unmet need for safer, better-tolerated therapies.
XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company, believes it has a solution in XORLO™, a proprietary formulation of oxypurinol. Unlike traditional oxypurinol, which has historically suffered from poor oral absorption, XORLO utilizes a liposomal delivery system to achieve high bioavailability and rapid absorption. This allows for effective uric acid lowering at substantially lower total daily doses, minimizing toxic-level exposure and severe gastrointestinal side effects. As a result, XORLO could offer a differentiated treatment option for gout patients who struggle with current standards of care.
The company is making tangible progress toward bringing XORLO to market. Recently, XORTX announcing the launch of drug material and tablet manufacturing to support a planned two-part clinical study known as XRX-OXY-102. This study is designed to characterize the pharmacokinetics and efficacy of XORLO and is being advanced based on positive prior clinical results and discussions with the FDA. The production of GMP drug substance and clinical supply tablets, representative of the intended commercial product, has already begun with a contract manufacturing partner.
Regulatory milestones are also on the horizon. XORTX is working toward a new drug application submission for XORLO, with a new Investigational New Drug application prepared for submission to the FDA in the fourth quarter of 2026. If the two-part clinical trial is successful, the company intends to request a pre-NDA meeting and prepare an NDA submission while simultaneously engaging in pre-commercialization activities. XORTX is targeting an NDA submission in about one year and estimates a market opportunity of $700 million annually for XORLO.
For investors and patients alike, these developments signal a potential shift in the gout treatment landscape. With its novel formulation and clear regulatory strategy, XORTX is positioning itself to address a growing patient population that desperately needs better options. As the company continues to hit manufacturing and regulatory milestones, the path to market for XORLO is becoming clearer. More information about XORTX can be found on XORTX.
